Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: The effect of adjuvants on mucosal and serum antibody responses

Immunology

Volumn 93, Issue 4, 1998, Pages 563-571

  Ugozzoli, M ^a   O'Hagan, D T ^a   Ott, G S ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI ENTEROTOXIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; ISCOM; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NEUTRALIZING ANTIBODY; POLYGLACTIN; QUIL A; VIRUS GLYCOPROTEIN; WATER OIL CREAM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG FORMULATION; ENCAPSULATION; FEMALE; HERPES SIMPLEX VIRUS 2; IMMUNIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; VERO CELL; VIRUS NEUTRALIZATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FECES; FEMALE; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; NASAL LAVAGE FLUID; SALIVA; SIMPLEXVIRUS; VAGINA; VIRAL ENVELOPE PROTEINS;

EID: 0031917995     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.1998.00441.x     Document Type: Article

References (38)

1. NAHMIAS A.J., LEE F.K. & BECKMAN-NAHMIAS S. (1990) Seroepidemiological and sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl 69, 19.
2. COREY L. & HOLMES K.K. (1983) Genital herpes simplex infections: current concepts in diagnosis, therapy and prevention. Ann Intern Med 98, 973.
3. JOHNSON R.E., NAHMIAS A.J., MAGDER L.S., LEE F.K., BROOKS C.A. & SNOWDEN C.B. (1989) A seroepidemiologic survey of the presence of herpes simplex virus type 2 infection in the United States. N Engl J Med 321, 321.
4. FORSGREN M. (1990) Genital herpes simplex viral infection and incidence of neonatal disease in Sweden Scand J Infect Dis Suppl 60, 37.
5. JOHNSON R.M. & SPEAR P.G. (1989) Herpes simplex virus glycoprotein D mediated interference with herpes simplex virus infections. J Virol 63, 819.
6. STUVE L.L., BROWN-SHIMER S., PACHL C., NAJARIAN, R., DINA D. & BURKE R.I. (1987) The structure and expression of herpes simplex virus type 2 glycoprotein gB2 gene. J Virol 61, 326.
7. SANCHEZ-PESCADOR L., BURKE R.L., OTT G. & VAN NEST G. (1988) The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine. J Immunol 141, 1720.
8. RENEGAR K.B. & SMALL P.A. (1991) Passive transfer of local immunity to influenza virus infection by IgA antibody. J Immunol 146, 1972.
9. WINNER L.S. III., MACK J., WELTZIN R., MEKALANOS J.J., KRAEHENBUHL J.P. & NEUTRA M.R. (1991) New model for analysis of mucosal immunity: Intestinal secretion of specific monoclonal immunoglobulin A from hybridoma tumours protects against Vibrio cholerae infection. Infect Immun 59, 977.
10. O'HAGAN D.T. (1994) Oral immunization and the common mucosal immune system. In: Novel Delivery Systems for Oral Vaccines (ed. D. T. O'Hagan), p. 1. CRC Press, Boca Raton.
11. OTT G., BARCHFELD G.L., CHERNOFF D., RADHAKRISHNAN R., VAN HOOGEVEST P. & VAN NEST G. (1995) MF59: design and evaluation of a safe and potent adjuvant for human vaccines. In: Vaccine Design: The Subunit and Adjuvant Approach (eds M. Powell & M. J. Newman), p. 277. Plenum Press, New York.
12. MOREIN B., SUNDQUIST B., HOGLUND S., DALSGAARD K. & OSTERHAUS P. (1984) Iscom, a novel structure for antigen presentation of membrane proteins from enveloped viruses. Nature 308, 457.
13. O'HAGAN D.T. (1996) The prospects for the development of new and improved vaccines through the use of microencapsulation technology. In: New Generation Vaccines (eds M. M. Levine, G. C. Woodrow, J. B. Kaper & G. S. Cobon), pp. 215-228. Marcel Dekker, New York.
14. PIZZA M., DOMENIGHINI M., HOL W. et al. (1994) Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis. Mol Microbiol 14, 51.
15. JEFFERY H., DAVIS S.S. & O'HAGAN D.T. (1993) Preparation and characterization of poly (lactide-co-glycolide) microparticles: II Protein entrapment by water-in-oil-in-water emulsion solvent evaporation. Pharm Res 10, 362.
16. SHARIF S., WHEELER A. & O'HAGAN D.T. (1995) Biodegradable microspheres as a delivery system for the allergens of Dermatophagoides pteronysinus (house dust mite): I Preparation and characterization of microparticles. Int J Pharm 119, 239.
17. LÖVGREN K., LINDMARK J., PIPCORN R. & MOREIN B. (1987) Antigenicity of small molecules and synthetic peptides conjugated to a preformed iscom as carrier. J Immunol Meth 96, 137.
18. HANEBORG B., KENDALL D., AMERONGEN H.M., APTER F.M., KRAEHENBUHL, J-P. & NEUTRA M.R. (1994) Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces. Inject Immun 62, 15.
19. JACKSON R.J., FUJIHASHI K., KYONO H. & MCGEE J.R. (1996) Luminometry: a novel bioluminescent immunoassay enhances the quantitation of mucosal and systemic antibody responses. J Immunol Methods 190(2), 189.
20. LANGENBERG A., BURKE R.L., ADAIR S. et al. (1996) A recombinant glycoprotein vaccine for herpes simplex type 2: safety and efficacy. Ann Int Med 122(12), 889.
21. GIULIANI M.M., DEL GIUDICE G., GIANELLI V., DOUGAN G., RAPPUOLI R. & PIZZA M. (1998) Mucosal adjuvanticity and immunogenicity of Escherichia coli neat labile enterotoxin (LT) mutants partially or completely detoxified by genetic engineering. Infect Immun in press.
22. WU, H-Y. & RUSSELL M.W. (1993) Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect Immun 61, 314.
23. RUSSELL M.W., MOLDOVEANU Z., WHITE P.L., SIBERT G.J., MESTECKY J. & MICHALEK S.M. (1996) Salivary, nasal, genital and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the cholera toxin B subunit. Infect Immun 64, 1272.
24. DI TOMMASO A., PINKAS H. & PENCEV D. (1996) Induction of antigen specific antibodies in vaginal secretions by using a nontoxic mutant of heat labile enterotoxin as a mucosal adjuvant. Inject Immun 64, 974.
25. HASHIGUCCI K., OGAWA H., YAMASHITA R. et al. (1996) Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit contaiing a trace amount of the holotoxin. Vaccine 14, 113.
26. SHAHIN R., LEEF M., ELDRIDGE J., HUDSON M. & GILLEY R. (1995) Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly (D, L-lactide-co-glycolide) microspheres. Infect Immun 63, 1195.
27. CAHILL E.S., ILLUM L., BARNARD A., MILLS K.H. & REDHEAD K. (1995) Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin. Vaccine 13, 455.
28. YAN C., RILL W.L., MALLI R. et al. (1996) Intranasal stimulation of long-lasting immunity against aerosol ricin challenge with ricin toxoid vaccine encapsulated in polymeric microspheres. Vaccine 14, 1031.
29. SCHWENDEMEN S.P., COSTANTINO H.R., GUPTA R.K., SIBER G.R., KLIBANOV A.M. & LANGER R. (1995) Stabilization of tetanus and diphtheria toxoids against moisture induced aggregation. Proc Natl Acad Sci USA 92, 11-234.
30. UCHIDA T., MARTIN S., FOSTER T.P., WARDLEY R.C. & GRIM S. (1994) Dose and load studies for subcutaneous and oral delivery of poly (lactide-co-glycolide) microspheres containing ovalbumin. Pharm Res 11, 1009.
31. KAZANJI M., LAURENT F. & PERY P. (1994) Immune responses and protective effect in mice vaccinated orally with surface sporozoite protein of Eimeira falcoformis in iscoms. Vaccine 12, 798.
32. MOWAT A., DONACHIE M.C.I., REID G. & JARRET O. (1991) Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunology 72, 317.
33. THAPARR M.A., PARR E.L., BOZZOLA J.J. & PARR M.B. (1991) Secretory immune response in the mouse vagina after parenteral or intravaginal immunization with an immunostimulating complex (Iscom). Vaccine 9, 129.
34. O'HAGAN D.T., RAFFERTY D., MCKEATING J.A. & ILLUM L. (1992) Vaginal immunization of rats with a synthetic peptide from human immunodeficiency virus envelope glycoprotein. J Gen Virol 73, 2141.
35. ELDRIDGE J.H., STAAS J.K., MEULBROEK J.A., TICE T.R. & GILLEY R.M. (1991) Biodegradable and biocompatible poly (DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal entcrotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun 59, 2978.
36. O'HAGAN D.T., RAHMAN D., MCGEE J.P. et al. (1991) Biodegradable microparticles as controlled release antigen systems. Immunology 73, 239.
37. O'HAGAN D.T. (1994) Microparticles as oral vaccines. In: Novel Delivery Systems for Oral Vaccines (ed. D. T. O'Hagan), pp. 175-205. CRC Press, Boca Raton.
38. LÖVGREN-BENGTSSON K. & SJOLANDER A. (1996) Adjuvant activity of iscoms: effect of ratio and co-incorporation of antigen and adjuvant. Vaccine 14, 753.